New Developments in Early-Stage Breast Cancer Treatment
The aim of treatment for early breast cancer is to eliminate the disease and reduce the chance of it returning. Recent advances help us understand who needs more intensive treatment and who may safely receive less. Decisions bring together the tumour’s characteristics, lymph node findings and the patient’s life, with input from surgery, medical oncology, radiation oncology and pathology. Oestrogen and progesterone receptors and HER2 status remain central to planning care. In suitable patients with hormone receptor-positive, HER2-negative disease, tests measuring gene activity in the tumour can help assess the likely benefit of chemotherapy. Some patients can therefore receive endocrine therapy without chemotherapy. Age, menopausal status and lymph node involvement also matter; the same test result does not lead to the same decision for everyone. [1] For hormone receptor-positive, HER2-negative disease at high risk of recurrence, adding a CDK4/6 inhibitor such as abemaciclib or ribociclib to endocrine therapy can offer additional protection. These medicines are alternatives, not used together, and their eligibility criteria differ. Updated monarchE results show a survival benefit with abemaciclib, while longer-term NATALEE follow-up supports a sustained reduction in recurrence with ribociclib. [2,3] In HER2-positive disease, the response to treatment before surgery increasingly guides subsequent care. In 2026, the antibody–drug conjugate trastuzumab deruxtecan received US approval for two early-stage settings: as part of a specified preoperative sequence for stage II–III disease, and after surgery when invasive cancer remains following preoperative trastuzumab and taxane-based treatment. This option requires careful monitoring for side effects, including inflammation of the lungs. [4] In high-risk early triple-negative breast cancer, adding pembrolizumab to chemotherapy before surgery and continuing pembrolizumab afterwards can improve survival. For patients with inherited BRCA1 or BRCA2 changes and high-risk, HER2-negative disease, olaparib after chemotherapy and local treatment offers another option. Genetic counselling and inherited gene testing can therefore directly influence treatment for eligible patients. [5,6] Progress also includes reducing the burden of local treatment. Selected low-risk patients whose lymph nodes appear clear on clinical assessment may avoid sentinel lymph node biopsy. Suitable patients may also receive breast radiotherapy over one week in five sessions; the 2026 long-term FAST-Forward results support this approach. These decisions aim to reduce treatment burden while maintaining effective care. [7,8] Each patient’s needs are different. The potential benefits, side effects and availability of newer options in Türkiye should be discussed openly, keeping the patient’s questions, concerns and everyday life part of the plan throughout treatment. Sources [1] TAILORx · NCI | [2] monarchE · 2026 | [3] NATALEE · 5 years | [4] HER2 · FDA 2026 | [5] KEYNOTE-522 · NEJM | [6] OlympiA · NEJM | [7] ASCO · 2025 | [8] FAST-Forward · 2026
The treatment plan is based on estrogen and progesterone receptors and HER2 results. In hormone receptor-positive, HER2-negative disease, tests measuring the gene activity of the tumor, performed on suitable patients, can help evaluate the expected benefit from chemotherapy. Thus, it is possible to be satisfied with hormone therapy in some patients. However, age, menopausal status and lymph node involvement are also important; a single test result does not give the same decision for everyone. [1]
In hormone receptor-positive, HER2-negative disease with a high risk of relapse, adding CDK4/6 inhibitors such as abemasiclib or ribociclib to hormone therapy can provide additional protection in suitable patients. These two drugs are not used together and the selection criteria are different. While current monarchE results show a benefit in survival with abemasiclib, long-term follow-up of NATALEE supports the continued effect of ribociclib in reducing the risk of relapse. [2,3]
In HER2-positive disease, treatment is becoming even more personalized based on the response to preoperative medication. In 2026, antibody-mediated chemotherapy called trastuzumab deruxtecan received approval in the US for two early-stage uses: as part of a specific preoperative treatment sequence in stage II–III disease, and postoperatively in patients who have remaining tumor tissue in the surgical specimen despite preoperative trastuzumab and taxane-containing treatment. Side effects, including pneumonia, are carefully monitored when this option is considered. [4]
In triple-negative breast cancer, adding pembrolizumab to preoperative chemotherapy and continuing pembrolizumab postoperatively in high-risk early-stage patients can prolong survival. In HER2-negative and high-risk patients with hereditary BRCA1 or BRCA2 alterations, olaparib can be an additional option after chemotherapy and local treatments. Therefore, genetic counseling and hereditary gene testing directly contribute to treatment decisions in appropriate patients. [5,6]
Progress is not limited to new drugs. In selected low-risk patients with clinically clear lymph nodes, axillary lymph node sampling can be omitted. In radiotherapy, five-session, one-week treatments reduce the treatment burden in suitable patients; FAST-Forward's 2026 long-term results support this approach. These decisions aim to reduce the burden on the patient without reducing the necessary treatment. [7,8]
Every patient's needs are different. The expected benefits, potential side effects, and accessibility of new options in Türkiye should be openly discussed; the patient's questions, concerns, and daily life should also be included in the treatment plan.
Sources [1] TAILORx · NCI | [2] monarchE · 2026 | [3] NATALEE · 5 years | [4] HER2 · FDA 2026 | [5] KEYNOTE-522 · NEJM | [6] OlympiA · NEJM | [7] ASCO · 2025 | [8] FAST-Forward · 2026
